New triple pill combo aims to tame stubborn diabetes

NCT ID NCT07244003

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Dec 08, 2025 · Last updated May 24, 2026 · Updated 27 times

Summary

This study tests whether a combination of three diabetes drugs (metformin, SGLT-2 inhibitor, and GLP-1 receptor agonist) works better than other oral medications for people with type 2 diabetes who have poor blood sugar control. About 430 adults aged 18-75 with a BMI of 20 or higher will participate. The goal is to see if this triple therapy helps lower blood sugar, blood pressure, and cholesterol more effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (TYPE 2 DIABETES MELLITUS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tianjin Medical University General Hospital
RECRUITING

Tianjin, Tianjin Municipality, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T2DM (TYPE 2 DIABETES MELLITUS) T2DM (TYPE 2 DIABETES MELLITUS)